冬凌草单药及与化疗合用治疗食管癌205例

目的:观察冬凌草单药及与化疗合用治疗食管癌的临床疗效.方法:448例患者,均经病理细胞学和X线检查确诊为食管癌.其中早期癌76例,均采用冬凌草单药治疗.晚期癌372例,167例采用冬凌草单药治疗,205例采用冬凌草与化疗合用.结果:用冬凌草单药治疗早期食管癌患者3,5,10,13 a的生存率明显高于未治疗组(98.68% vs 51.52%,84.02% vs 28.62%,63.49% vs 11.45%,50.13% vs 8.59%;P<0.001).对于晚期食管癌,冬凌草联合化疗应用,其总有效率明显高于以PYM(BLM)为基础的单一化疗(66.82% vs 42.85%,P<0.01).冬凌草与化疗合用组与单一化疗对照组相比副作用基本相同,无明显差异(P>0.05).结论:对于早期食管癌患者,冬凌草能控制疾病发展延长生存时间;对于晚期食管癌患者,冬凌草能增强化疗的作用.     

乳腺良恶性病变的磁共振T2*W首过灌注成像与血管生成相关性研究

Objective： To study the diagnostic value of T2^＊-weighted first-pass perfusion imaging in breast tumors. Methods： We analyzed the magnetic resonance imaging （MRI） information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^＊-weighted first-pass perfusion imaging. The curve＇s maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results： Malignant breast lesions showed higher maximal signal intensity drop rate （44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001） than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions （23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05）. Conclusion： The T2^＊-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis.     

肝细胞癌合并胆管癌栓患者术中癌栓的处理

目的 探讨肝细胞癌（HCC）合并胆管癌栓患者术中癌栓的处理方式和术后恢复过程。方法 对1995年1月-2002年12月手术治疗的27例HCC合并胆管癌栓情况进行回顾性总结和分析。结果 只有59．3％（16／27）患者行肝切除、胆管取癌栓及胆管引流术。全组术后并发症发生率为55．6％（15／27），术后30d病死率为22．2％（6／27）。结论 HCC合并胆管癌栓的预后差，早期诊断和外科手术治疗是改善此病预后的关键。     

11^C-蛋氨酸的体内生物学分布和初步临床应用

目的研究新型脑肿瘤显像剂：11^C-蛋氨酸（11^C-MET）的体内生物学分布，探讨11^C—MET的临床显像方法及其在脑肿瘤显像中的应用．方法测定11^C—MET在小鼠体内的分布，对健康志愿者和病理证实胶质瘤患者进行PET脑显像．结果小鼠体内分布实验和脑PET显像发现，11^C—MET在血液中清除较慢，在肿瘤内有较长的滞留时问，平台期位于30—45min之间，延迟相对有利于脑瘤的显像，其余放射性主要集中在消化系统．结论11^C—MDT有较高的肿瘤／脑比值，是理想的脑肿瘤显像剂．     

骨外型牙源性钙化上皮瘤1例报告

牙源性钙化上皮瘤是一种良性肿瘤，也称Pindborg瘤，可分为骨内型和骨外型2种，主要发生于颌骨内，偶见于颌骨外。本文报告1例发生于口底的牙源性钙化上皮瘤，其临床症状与口底皮样囊肿相似．术后经组织病理学确诊，主要组织病理学特征是嗜酸性环状钙化团块。因其具有局部侵袭性，为避免复发，提倡完整切除肿物。     

食管支架置入术的临床应用

目的探讨食管支架置入术对良、恶性食管狭窄和食管瘘的治疗方法、疗效和并发症的处理。方法对55例不同原因所致良、恶性食管狭窄和食管瘘患者采用食管金属支架置入术。结果食管狭窄的主要症状吞咽困难、呛咳得到改善，近期疗效达100％。出现的并发症主要为疼痛和大便隐血，发生率分别为100％和92．7％，其余依次为胃食管返流、食管再狭窄、支架脱落，经过治疗后得到缓解或消失。结论金属支架置入术是治疗中晚期食管癌、狭窄的有效方法之一，对食管良性狭窄和瘘效果亦好。并发症可以预防，处理后大部分缓解。     

密盖息治疗49例恶性骨转移瘤疗效观察

目的:观察密盖息(鲑鱼降钙素)的治疗骨转移瘤疼痛和血清钙的临床疗效。方法:单用组用密盖息100IU,肌肉注射,每日2次,共7d。联合化疗组化疗后加密盖息100IU肌肉注射,每日2次,每次7d。治疗结束进行疗效评价。结果:单用组骨痛完全缓解66.7%(12/18)。联合化疗组骨痛完全缓解率87.1%(27/31)。单用组血钙降至正常,占77.8%(14/18),联合化疗组血钙完全降至正常占100%(31/31)。副作用是暂时性的心动过速、皮肤潮红、头晕、恶心呕吐,无需特殊处理,自行缓解。结论:密盖息治疗骨转移瘤有止痛、降低血钙作用良好,副作用小,可以在临床上安全使用。     

Repeat Transarterial Chemoembolization (TACE) for Progressive Hepatic Carcinoid Metastases Provides Results Similar to First TACE

Background Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from repeat TACE. Methods The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier method. Results Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict survival after repeat TACE. Conclusion Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is safe and offers a viable treatment option. Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007.     

经乙状窦后入路显微手术治疗继发性三叉神经痛37例

目的探讨经乙状窦后入路显微手术治疗桥小脑角占位性病变引起的继发性三叉神经痛的疗效。方法回顾分析我院2000年10月～2006年7月37例继发性三叉神经痛的临床资料，其中胆脂瘤18例，脑膜瘤8例，听神经瘤6例，三叉神经鞘瘤5例，均经乙状窦后入路显微手术切除肿瘤。结果肿瘤全切23例，次全切除10例，部分切除4例。35例疼痛症状消失（32例立即消失，3例术后2个月消失），随访3个月～5年无复发；2例无效。发生暂时性面瘫6例，面部麻木6例，无颅内感染及脑脊液漏。结论经乙状窦后入路显微手术是治疗继发性三叉神经痛安全有效的方法。     

内蒙古地区食管癌组织中人乳头瘤病毒的检测

目的:了解内蒙古地区HPV感染与食管癌的关系,探讨HPV在食管癌病因学中的作用.方法:应用通用引物PCR法检测食管癌标本中HPV DNA.结果:在来自内蒙古地区41例食管癌标本中,HPV DNA检出率为零.结论:内蒙古地区食管癌发生可能与HPV感染无关.